Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCENDO: Escalating Cycle 1 Dose of Lu-177-PSMA-617 in mCRPC
NCT07682649Phase 1Not yet recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Dose Limiting Toxicity up to 6 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07682649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07682649.